Federal Register Notice: The Science Board to the FDA will meet 3/1, from 8:30 a.m. until 5 p.m. at FDA’s White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503, Section A), Silver Spring, MD. For those unable to attend in person, the meeting will also be webcast at https://collaboration.fda.gov/scienceboard0316/. The Science Board will hear about and discuss: (1) The role of opioids in pain management; (2) scientific challenges facing FDA in supporting the development of pain medications, including opioids, that have reduced risks of being abused; (3) scientific challenges facing FDA in seeking to understand the real-world use of opioids to treat pain, including the impact of opioids with potentially less risk for abuse; (4) the role that FDA plays as a part of a larger federal, state, and local response to the challenges of providing appropriate pain treatment while reducing opioid abuse; and (5) postmarket surveillance activities related to opioids. The Science Board will also receive a final report from the Centers of Excellence in Regulatory Science and Innovation Program Evaluation Subcommittee. Contact Rakesh Raghuwanshi, (301) 796-4769, rakesh.raghuwanshi@fda.hhs.gov. To view this notice, click here.